FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1982486930> ?p ?o ?g. }

• W1982486930 endingPage "2085" @default.
• W1982486930 startingPage "2081" @default.
• W1982486930 abstract "No AccessJournal of UrologyAdult Urology1 Dec 2013Does the Number of Cycles of Cisplatin Based Chemotherapy Have any Effect on Renal Function in Patients with Testicular Germ Cell Tumor? Evren Suer, Murat Mermerkaya, Ömer Gülpınar, Faraj Afandiyev, Sümer Baltacı, Kadir Türkölmez, and Yaşar Bedük Evren SuerEvren Suer More articles by this author , Murat MermerkayaMurat Mermerkaya More articles by this author , Ömer GülpınarÖmer Gülpınar More articles by this author , Faraj AfandiyevFaraj Afandiyev More articles by this author , Sümer BaltacıSümer Baltacı More articles by this author , Kadir TürkölmezKadir Türkölmez More articles by this author , and Yaşar BedükYaşar Bedük More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.06.009AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We assessed the effects of the number of cisplatin, etoposide and bleomycin cycles on long-term renal function. Materials and Methods: A total of 157 patients with primary testicular germ cell tumors were treated between 1995 and 2013, of whom 113 (72%) received chemotherapy as the primary intervention. Data were collected retrospectively. The estimated glomerular filtration rate was determined using the Modification of Diet in Renal Disease (MDRD) formula based on pretreatment and last followup visit serum creatinine measurements. Patients who did not receive chemotherapy were compared to those who received cisplatin based chemotherapy. The chemotherapy group was also divided into 3 subgroups according to the number of chemotherapy cycles (2, 3, or 4 or more). Results: At the last followup visit serum creatinine and the estimated glomerular filtration rate significantly differed between the chemotherapy and nonchemotherapy groups. The decrease in the median estimated glomerular filtration rate was significantly greater in the chemotherapy than the nonchemotherapy group (p <0.001). New onset stage 3 chronic kidney disease was observed in 19 patients (12.1%) in the chemotherapy group, including 0%, 5.9%, 13.8% and 20.9% who received 0, 2, 3, or 4 or more chemotherapy cycles, respectively. Except for the difference between the nonchemotherapy group and the 2-cycle chemotherapy group the differences between the groups in new onset chronic stage 3 kidney disease were statistically significant. Conclusions: Patients with testicular tumors who received cisplatin based chemotherapy showed a significant decrease in the estimated glomerular filtration rate and a significant increase in new onset stage 3 chronic kidney disease compared to patients who received no cycle. However, in patients at high risk with stage I nonseminomatous germ cell tumor who elected 2 cycles of cisplatin, etoposide and bleomycin the chemotherapy had no statistically significant effect on these parameters compared to those in patients who received no chemotherapy. References 1 : Testicular germ-cell cancer. N Engl J Med1997; 337: 242. Google Scholar 2 : Cancer mortality in Europe, 2000-2004, and an overview of trends since 1995. Ann Oncol2010 Jun.; 21: 1323. Google Scholar 3 : The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol2012; 61: 1212. Google Scholar 4 : European Association of Urology EAU guidelines on testicular cancer: 2011 update. Eur Urol2011; 60: 304. Google Scholar 5 : Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst2010; 102: 1114. Google Scholar 6 : Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol2002; 13: 222. Google Scholar 7 : Effect of testicular germ cell tumor therapy on renal function. Urology2012; 80: 641. Google Scholar 8 : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004; 351: 1296. Google Scholar 9 : Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol2008; 167: 1226. Google Scholar 10 : Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate. Ann Intern Med2006; 145: 247. Google Scholar 11 : The graying of testis cancer patients: what have we learned?. J Clin Oncol2007; 25: 4341. Google Scholar 12 : Cancer survivorship—genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst2006; 98: 15. Google Scholar 13 : Complications of systemic therapy for genitourinary malignancies. AUA Update Series2005; : 24. Google Scholar 14 : Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. Clin Sci (Lond)1988; 75: 203. Google Scholar 15 : Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer1986; 54: 19. Google Scholar 16 : Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol1988; 21: 163. Google Scholar 17 : Treatment- specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol2007; 25: 4370. Google Scholar 18 : Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol2000; 18: 1725. Google Scholar 19 : Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol2010; 28: 4649. Google Scholar 20 : Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol1992; 10: 574. Google Scholar 21 : Late toxicity following curative treatment of testicular cancer. Semin Surg Oncol1999; 17: 275. Google Scholar 22 : Renal function related to different treatment modalities for malignant germ cell tumours. Br J Cancer1990; 62: 842. Google Scholar 23 : Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med2012; 156: 785. Google Scholar 24 : Measurement of kidney function. Med Clin North Am2005; 89: 457. Google Scholar 25 : Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. J Urol2006; 176: 1996. Link, Google Scholar 26 : Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys1990; 19: 977. Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 190Issue 6December 2013Page: 2081-2085Supplementary Materials Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordskidneychronicgerm cell and embryonalcisplatinneoplasmstestisrenal insufficiencyMetricsAuthor Information Evren Suer More articles by this author Murat Mermerkaya More articles by this author Ömer Gülpınar More articles by this author Faraj Afandiyev More articles by this author Sümer Baltacı More articles by this author Kadir Türkölmez More articles by this author Yaşar Bedük More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W1982486930 created "2016-06-24" @default.
• W1982486930 creator A5013839598 @default.
• W1982486930 creator A5021277050 @default.
• W1982486930 creator A5027616253 @default.
• W1982486930 creator A5050927873 @default.
• W1982486930 creator A5061087280 @default.
• W1982486930 creator A5064178304 @default.
• W1982486930 creator A5088211515 @default.
• W1982486930 date "2013-12-01" @default.
• W1982486930 modified "2023-10-16" @default.
• W1982486930 title "Does the Number of Cycles of Cisplatin Based Chemotherapy Have any Effect on Renal Function in Patients with Testicular Germ Cell Tumor?" @default.
• W1982486930 cites W2013093345 @default.
• W1982486930 cites W2029714546 @default.
• W1982486930 cites W2037207094 @default.
• W1982486930 cites W2062928336 @default.
• W1982486930 cites W2065722985 @default.
• W1982486930 cites W2073742622 @default.
• W1982486930 cites W2100690580 @default.
• W1982486930 cites W2103988358 @default.
• W1982486930 cites W2104095601 @default.
• W1982486930 cites W2109175854 @default.
• W1982486930 cites W2113967524 @default.
• W1982486930 cites W2126505950 @default.
• W1982486930 cites W2128718811 @default.
• W1982486930 cites W2129913824 @default.
• W1982486930 cites W2136361773 @default.
• W1982486930 cites W2145632027 @default.
• W1982486930 cites W2146458161 @default.
• W1982486930 cites W2161993385 @default.
• W1982486930 cites W2162378916 @default.
• W1982486930 cites W2175942611 @default.
• W1982486930 cites W2204426862 @default.
• W1982486930 cites W2325651197 @default.
• W1982486930 cites W2398011703 @default.
• W1982486930 cites W2917270815 @default.
• W1982486930 cites W3025346697 @default.
• W1982486930 doi "https://doi.org/10.1016/j.juro.2013.06.009" @default.
• W1982486930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23764076" @default.
• W1982486930 hasPublicationYear "2013" @default.
• W1982486930 type Work @default.
• W1982486930 sameAs 1982486930 @default.
• W1982486930 citedByCount "11" @default.
• W1982486930 countsByYear W19824869302013 @default.
• W1982486930 countsByYear W19824869302014 @default.
• W1982486930 countsByYear W19824869302015 @default.
• W1982486930 countsByYear W19824869302017 @default.
• W1982486930 countsByYear W19824869302020 @default.
• W1982486930 countsByYear W19824869302021 @default.
• W1982486930 countsByYear W19824869302023 @default.
• W1982486930 crossrefType "journal-article" @default.
• W1982486930 hasAuthorship W1982486930A5013839598 @default.
• W1982486930 hasAuthorship W1982486930A5021277050 @default.
• W1982486930 hasAuthorship W1982486930A5027616253 @default.
• W1982486930 hasAuthorship W1982486930A5050927873 @default.
• W1982486930 hasAuthorship W1982486930A5061087280 @default.
• W1982486930 hasAuthorship W1982486930A5064178304 @default.
• W1982486930 hasAuthorship W1982486930A5088211515 @default.
• W1982486930 hasConcept C104317684 @default.
• W1982486930 hasConcept C126322002 @default.
• W1982486930 hasConcept C126894567 @default.
• W1982486930 hasConcept C14036430 @default.
• W1982486930 hasConcept C143998085 @default.
• W1982486930 hasConcept C159641895 @default.
• W1982486930 hasConcept C185592680 @default.
• W1982486930 hasConcept C2776212926 @default.
• W1982486930 hasConcept C2776694085 @default.
• W1982486930 hasConcept C2776938808 @default.
• W1982486930 hasConcept C2778239845 @default.
• W1982486930 hasConcept C2779122487 @default.
• W1982486930 hasConcept C2911180711 @default.
• W1982486930 hasConcept C55493867 @default.
• W1982486930 hasConcept C71924100 @default.
• W1982486930 hasConcept C86803240 @default.
• W1982486930 hasConcept C95444343 @default.
• W1982486930 hasConceptScore W1982486930C104317684 @default.
• W1982486930 hasConceptScore W1982486930C126322002 @default.
• W1982486930 hasConceptScore W1982486930C126894567 @default.
• W1982486930 hasConceptScore W1982486930C14036430 @default.
• W1982486930 hasConceptScore W1982486930C143998085 @default.
• W1982486930 hasConceptScore W1982486930C159641895 @default.
• W1982486930 hasConceptScore W1982486930C185592680 @default.
• W1982486930 hasConceptScore W1982486930C2776212926 @default.
• W1982486930 hasConceptScore W1982486930C2776694085 @default.
• W1982486930 hasConceptScore W1982486930C2776938808 @default.
• W1982486930 hasConceptScore W1982486930C2778239845 @default.
• W1982486930 hasConceptScore W1982486930C2779122487 @default.
• W1982486930 hasConceptScore W1982486930C2911180711 @default.
• W1982486930 hasConceptScore W1982486930C55493867 @default.
• W1982486930 hasConceptScore W1982486930C71924100 @default.
• W1982486930 hasConceptScore W1982486930C86803240 @default.
• W1982486930 hasConceptScore W1982486930C95444343 @default.
• W1982486930 hasIssue "6" @default.
• W1982486930 hasLocation W19824869301 @default.
• W1982486930 hasLocation W19824869302 @default.
• W1982486930 hasOpenAccess W1982486930 @default.
• W1982486930 hasPrimaryLocation W19824869301 @default.
• W1982486930 hasRelatedWork W1987760594 @default.

• next